Everything drug pricing and policy, every day
Still, links to ponder on CMS hospital payments, the price of gene therapies, and UK price negotiations
And more 340B stories than you can shake a stick at
And a CMS advisor offers a peek behind the curtain on the agency’s myriad drug-pricing workstreams
And could states create a “Netflix” model to balance obesity-med spending and access?
And a Health Affairs Forefront piece brings much-needed clarity to the 340B rebate model conversation
Drugmakers and the government argue 340B rebate models in federal appeals court
And a ranked list of a dozen other stories from the past 96 hours
